Semaglutide for the management of diabesity: The real-world experience

Table 1 Baseline characteristics of 106 type 2 diabetes mellitus patients treated with semaglutide

Attributes	Male		Female		All		Reference value (if applicable)
	Mean	(SD)	Mean	(SD)	Mean	(SD)
Patient age (years)	60.88	(10.04)	60.64	(12.43)	60.76	(11.18)
Systolic blood pressure (mm Hg)	140.43	(18.42)	136.79	(15.18)	138.86	(17.02)
Diastolic blood pressure (mm Hg)	80.32	(10.82)	71.32	(10.62)	76.45	(11.56)
Patient baseline weight (kg)	111.45	(21.07)	109.05	(28.63)	110.36	(24.56)
Patient baseline HbA1c (mmol/mol)	84.18	(22.20)	79.46	(19.40)	81.96	(20.96)	20-41 mmol/mol
Serum creatinine (μmol/L)	101.16	(53.98)	75.33	(37.18)	89.34	(48.52)	Male: 59-104 μmol/L; Female: 45-84 μmol/L
Urine ACR (mg/mmol)	21.96	(38.26)	28.74	(58.59)	24.97	(47.81)	Male: < 2.5 mg/mmol; Female: < 3.5 mg/mmol
Total cholesterol (mmol/L)	4.10	(1.47)	4.53	(1.16)	4.29	(1.35)	< 5.01 mmol/L
HDL (mmol/L)	1.07	(0.34)	1.16	(0.36)	1.11	(0.35)	> 1 mmol/L
Triglyceride (mmol/L)	4.82	(5.79)	5.02	(2.62)	4.89	(4.60)	< 2.3 mmol/L
ALT (U/L)	25.50	(15.04)	23.73	(11.17)	24.69	(13.33)	0-33 U/L

ALT: Alanine transaminase; ACR: Albumin creatinine ratio; HbA1c: Glycated hemoglobin; HDL: High-density lipoprotein.

Table 2 Treatment patients received for type 2 diabetes mellitus before initiation of semaglutide therapy

Medication	Total patients	Percentage (%)
Metformin	74	69.8
SGLT2 inhibitors	55	51.9
Sulfonylureas	27	25.5
Pioglitazone	7	6.6
Meglitinides	1	0.9
DPP4 inhibitors	6	5.7
Insulin	74	69.8
Anti-obesity medications	1	0.9

Table 3 Patients’ glycated hemoglobin before and after treatment with semaglutide

Attributes	Male		Female		All		Reference value (if applicable)
	Mean	(SD)	Mean	(SD)	Mean	(SD)
Patient baseline HbA1c (mmol/mol)	84.18	(22.20)	79.46	(19.40)	81.96	(20.96)	20-41 mmol/mol
HbA1c after 6 months (mmol/mol)	68.52	(21.06)	67.02	(15.66)	67.79	(18.53)	20-41 mmol/mol
HbA1c after 1 yr (mmol/mol)	71.42	(21.94)	63.27	(17.48)	66.91	(19.88)	20-41 mmol/mol
Latest HbA1c (mmol/mol)	72.98	(25.60)	68.2	(19.80)	70.73	(23.04)	20-41 mmol/mol

HbA1c: Glycated hemoglobin.

Table 4 Effect of semaglutide on glycemic control (glycated hemoglobin)

HbA1c	Mean	SD	df	Sig. (2-tailed) P value
HbA1c baseline to 6 month	12.31	17.926	47	0.000
HbA1c baseline to 1 yr	14.456	19.428	47	0.000
HbA1c baseline to latest	9.644	20.174	47	0.002

HbA1c: Glycated hemoglobin.

Table 5 Patient body weight before and after treatment with semaglutide

Attributes	Male		Female		All
	Mean	(SD)	Mean	(SD)	Mean	(SD)
Patient baseline weight (kg)	111.45	(21.07)	109.05	(28.63)	110.36	(24.56)
Weight after 6 months (kg)	100.19	(20.98)	100.39	(38.57)	100.27	(29.13)
Weight after 1 year (kg)	102.10	(25.96)	98.07	(25.35)	99.86	(24.94)
Latest weight (kg)	101.74	(18.21)	90.21	(22.93)	96.82	(22.88)

Table 6 Daily insulin requirement before and after treatment with semaglutide

Attributes	Male		Female		All
	Mean	(SD)	Mean	(SD)	Mean	(SD)
Daily insulin dose baseline (units)	106.00	(83.59)	81.89	(58.48)	95.02	(74.02)
Daily insulin dose latest (units)	92.2	(62.86)	62.14	(46.21)	76.45	(56.17)